



TRANSLATIONAL & COMPARATIVE MEDICAL RESEARCH (TCMR)

TCMR collaborates with external scientific organizations (biotechs, start-ups, universities, government agencies) to de-risk early human health drug discovery packages by applying proof-of-concept studies from the naturally occurring diseases in companion animals that parallel human diseases.

- An extensive full-service R&D unit within Elanco, a division of Eli Lilly and Company
- In-house veterinary scientists, clinical specialists, and operational experts
- Specialize in pre-clinical, drug development with a focus on informing go/no go decisions and creating strong proof-of-concept data packages
- Specialize in the design and implementation of companion animal studies in diseases with parallel human diseases, such as, but not limited to:
 - Oncology
 - Osteoarthritis
 - Gastroenterology
 - Endocrine
 - Pain
 - Autoimmune
 - Heart failure
 - Neurology

High-quality safety and efficacy data from companion animals with naturally occurring diseases that parallel human diseases can increase the marketability of proof-of-concept data packages, particularly for target diseases with high failure rates in Phase II and III clinical trials.

HAVE AN IDEA?

COLLABORATE WITH US.

► lilly.com/partners